和黃醫藥(00013.HK)2024年應佔淨收益爲3770萬美元 研發開支減少30%至2.121億美元
格隆匯3月19日丨和黃醫藥(00013.HK)公告,2024年,腫瘤產品市場銷售額增長134%至5.01億美元,得益於此,腫瘤產品綜合收入強勁增長65%至2.715億美元。2024年腫瘤/免疫業務綜合收入總額爲3.634億美元(2023年:5.286億美元),在3億美元至4億美元的指引範圍內。綜合收入總額爲6.302億美元(2023年:8.38億美元)。2024年和黃醫藥應佔淨收益爲3,770萬美元,而2023年則爲1.008億美元。
研發開支減少30%至2.121億美元(2023年:3.02億美元),減少主要是由於中國境外團隊重組,而美國及歐洲的臨牀及監管費用減少至3,450萬美元(2023年:1.069億美元)。中國投資爲1.776億美元(2023年:1.951億美元)。這反映了已完成並等待監管機構批準的研究成本下降,以及公司對內部產品管線中具有全球潛力的關鍵資產的持續承諾,包括新一代ATTC平臺的開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.